Onychomycosis

Authors

  • Simhavalli Godavarthi Avanthi Institute of Pharmaceutical Sciences, Tagarapuvalasa, Andhrapradesh
  • Bammidi Tushara Avanthi Institute of Pharmaceutical Sciences, Tagarapuvalasa, Andhrapradesh
  • Sri Hari Krishna Indurthi East Point College of Pharmacy, Avalahalli, Bangalore, Karnataka
  • Reddy Dhishitha East Point College of Pharmacy, Avalahalli, Bangalore, Karnataka

Keywords:

Onychoscopy, onychomycosis, nail invasion, antifungal lacquers

Abstract

Onychomycosis is the most common nail disorder. It is caused by variety of organisms mainly by dermatophytes. This fungal infection of nails leads to discolouration, thickening and separation from the nail bed. The clinical suspect of onychomycosis must be confirmed by mycology. Onychoscopy is the new technique that help physician in diagnosis of onychomycosis. Its treatment depends upon the modality of nail invasion, fungus species and the number of affected nails. Oral treatments are often combined by drug interactions, while topical antifungal lacquers have less efficacy. A combination of both oral and systemic treatment is the best choice.

Downloads

Download data is not yet available.

References

Medscape; by Antonella tasti,MD; October 25,2020.

Onychomycosis: Current trends in diagnosis & treatment by dyanne P. wester Berg, DO, and michel J.Voyack, DO. Cooper medical school of Rowan University, Camden, New Jersey-American family Physician; December 1, 2013-Volume 88, Number 11.

Heikkla, H; stubb, s. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 1995,133,699-703

Rosecuw, D. Achiller foot screening project: Preliminary results of patient screened by dermatologists; J. Eur.Acad. dermatol. Venereol.1999,12,S6-S9.

Scher, R.K., Rich, P., Pariser, d.,elewski, b.-the epidemiology, etiology & pathophysiology of onychomycosis. Semin. Cutan. Med. Surg. 2013,32, S2-S4.

Onychomycosis, From: Paediatric emergency medicine, 2008 by Roberto Arenas MD; Edoardo Torres-Guerrero MD.

Singal A & Khanna D. onychomysis diagnosis and management. Indian J Dermatol venereal Leprol 2013;77(6):659672.

Arrese, J.E.; Quatresooz, P.; Pierard-Franchimont, C.; Pierard, G.E. Nail histomycology.Protean aspects of a human fungal bed. Ann. Dermatol. Venereol. 2003,130, 1254-1259.

Baran R, Mcloone N, Hay RJ. Could Proximal White subrungual onychomycosis be a complication of systemic spread? The lessons to be learned from maladie dermatophytiychoque & other deep in fections. Br J Dermatol. 2005; 153:1023-1025.[PubMed].

Klaws W, Lowell AG, Stephen IL=K, Barbara AG, Amy SP, David JL. Fitzpatricks dermatology in general medicine. 7th edition Newyork; McGraw Hill;2007, pp. 778-794.

Tosti, A.; Baran, R; Piraccini, B, M,.; fanti,P.A. “endonyx” onychomycosis: A new modality of nail invasion by dermatophytes. Acta derm. Venereol. 1999,79,52-53.

Faergemann J, Baran R. epidermiology, clinical presentation & diagnosisof onychomycosis. Br J Dermatol. 2003;149(supp165): 1-4.

Allevato MA. Diseases mimicking onychomy cosis. Clin Dermatol. 2010;28(2): 164-177.

Tosti,A .; Baran, R.; Piraccini, B.M.; Fanti, P.A. “Endonyx” onychomycosis: A new modality of nail invasion by dermatophytes. Acta derm. Venereol. 1999, 79, 52-53.

Ex vivo Confocal laser scanning Microscopy: A potential New diagnostic Imaging tool in onychomycosis Comparable with Gold standard techniques.Sebastians Krammer,Christian Krammer, Gabriela vladimirova, Suzanna Salazer,cristel Ruini, Elke sattler, Lars E.french and daniela Hartman.; frontiers in medicine dermatology 06 November 2020.

Cinotti, E.;Fouillioux,B.;Perrot,J.L.; Labeille, B.;douchet,C.; Cambazard,F.Conocal microscopy for healthy and pathological nail. J.Eur.Acad.Dermatol.venereol.2014,28,853-858.

Tsunemi,Y.;Takehara,K.;Miura,Y.;Nakagami,G.;Sanada,H.;Kawashima,M.Screening for tinea Unquinum by dermatophyte test strip.Br.J.Dermator 2014,170,328-331.

Idriss,M.H.;Khali,A.;Elston,D.The diagnostic value of fungal fluorescence in onychomycosis J.Cutan.Pathol.2013,40,385-390.

Smijs,T.G.;Jachtenberg,J.W.;Pavel,S.;Bakker-Schut,T.C.;Willemse-Erix,D.;de Haas,E.R.;Sterenborg,H.Detection and differentiation of causative organisms of onychomycosis in an Ex Vivo nail model by means of Raman Spectroscopy.J.Eur.Acad.Dermatol.Venreol.2013,28,1492-1499.

Del Rosso, J.Q. the role of topical antifungal therapy for onychomycosis and the emergency of newer agents. J. Clin.Aesthet. Dermatol 2014, 7, 10-18.

Tieiz, H,J,; Hay, R.; Querner, S.; Delcker, A,; Kurka, P.; Merk, H.F.Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: A double-blind, randomized, placebo-controlled multicenter study. Mycoses 2013, 56,414-412.

Hay,R.J.; Baran, R.onychomycosis: A proposed revision of the clinical classification. J.AM Acad. Dermatol. 2011, 65,1219-1227.

Gupta, A.K.; Ryder, J.E.; Baran, R. The use of topical therapies to treat onychomycosis. Dermatol. Clin. 2003, 21, 481-489.

Gupta, A.K.; Paquet, M.; Simpson, F.C. Therapies for the treatment of onychomycosis. Clin. Dermatol.2013, 31, 544-554.

Elewski, B.E.; Rich, P.; Pollak, R.; Pariser, D.M.; Watanabe, S.; Senda, H.; Ieda, C.; Smith, K.; Pillai, R.; Ramakrishna,T.; et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomize, double-blind studies. J. Am. Acad. Dermatol. 2013, 68,600-608.

Elewski, B.E.; Tosti, A.Tavaborole for the treatment of onychomycosis. Expect Opin. Pharmacother. 2014, 15, 1439-1448.

Jones, T.; Tavakkol, A.Safty and Tolerability of Luliconazole solution 10% in patients with moderate to severe distal subungual onychomycosis. Antimicrobe. Agents chemother. 2013, 57,2684-2689.

Zhang, R.N.; Wang, D.K.; Zhuo, F.L.; Duan, X.H.; Zhang, X.Y.; Zhao, J.Y. Long-pulsed Nd: YAG 1064-nm laser treatment of onychomycosis . chin. Mrd. J. (engl.) 2012, 125, 3288-3291.

De Sa, D.C.’; Lamas, A.P.; Tosti, A. Oral therapy for onychomycosis: An evidence – based review. Am. J. Clin. Dermatol. 2014, 15, 17-36.

Gupta, A.K.; Paquet, M.; Simpson, F.; Tavakkol, A.Terbinafine in the treatment of dermatophyte toenail onychomycosis: A meta-analysis of efficacy for continuous and intermittent regimens. J. eur. Acad. Dermatol. Venereal. 2013, 27,267-272.

Gupta, A.K.; Drummond-Main, C.; Paquet, M. Evidence – based optimal fiuconazole dosing regimen for onychomycosis treatmrnt. J. Dermatol. Treat. 2013, 24, 75-80.

Published

2020-12-31
Statistics
168 Views | 113 Downloads
Citatons

How to Cite

Simhavalli Godavarthi, Bammidi Tushara, Sri Hari Krishna Indurthi, and Reddy Dhishitha. “Onychomycosis”. International Journal of Pharmaceutics and Drug Analysis, vol. 8, no. 12, Dec. 2020, pp. 1-5, https://ijpda.com/index.php/journal/article/view/445.

Issue

Section

Review Articles
Share |